|
The FDA has completed its review of the final clinical study report of ENHANCE and issued an update. Read the MedWatch safety summary, including links to the January 2008 FDA Early Communication and the January 2009 Update, at
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Ezetimibe
You are encouraged to report all serious adverse events and product quality problems for human medical products to MedWatch at: www.fda.gov/medwatch/report.htm.
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
